Shares of Agile Therapeutics (NASDAQ:AGRX) have earned a consensus rating of “Hold” from the seven research firms that are covering the firm, Marketbeat reports. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and four have given a buy rating to the company. The average 12 month price objective among brokers that have issued ratings on the stock in the last year is $7.67.
Several equities analysts have weighed in on the stock. Noble Financial restated a “buy” rating on shares of Agile Therapeutics in a report on Wednesday, March 14th. HC Wainwright restated a “buy” rating and set a $8.00 target price on shares of Agile Therapeutics in a report on Tuesday, March 13th. Janney Montgomery Scott downgraded shares of Agile Therapeutics from a “buy” rating to a “neutral” rating in a report on Thursday, December 28th. Finally, William Blair downgraded shares of Agile Therapeutics from an “outperform” rating to a “market perform” rating in a report on Tuesday, December 26th.
Shares of AGRX traded down $0.17 during trading hours on Thursday, reaching $2.73. The company had a trading volume of 92,778 shares, compared to its average volume of 92,636. The company has a market capitalization of $93.50, a PE ratio of -3.00 and a beta of 2.13. Agile Therapeutics has a 12-month low of $1.93 and a 12-month high of $5.60.
Agile Therapeutics (NASDAQ:AGRX) last announced its quarterly earnings results on Monday, March 12th. The specialty pharmaceutical company reported ($0.18) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.23) by $0.05. equities analysts forecast that Agile Therapeutics will post -0.71 EPS for the current fiscal year.
A number of large investors have recently bought and sold shares of AGRX. Perceptive Advisors LLC purchased a new position in Agile Therapeutics during the 4th quarter valued at about $9,092,000. Broadfin Capital LLC purchased a new stake in shares of Agile Therapeutics during the fourth quarter worth about $964,000. Renaissance Technologies LLC grew its holdings in shares of Agile Therapeutics by 313.7% during the fourth quarter. Renaissance Technologies LLC now owns 366,100 shares of the specialty pharmaceutical company’s stock worth $985,000 after buying an additional 277,600 shares in the last quarter. Russell Investments Group Ltd. purchased a new stake in shares of Agile Therapeutics during the third quarter worth about $943,000. Finally, Neuberger Berman Group LLC purchased a new stake in shares of Agile Therapeutics during the third quarter worth about $613,000. Hedge funds and other institutional investors own 71.03% of the company’s stock.
ILLEGAL ACTIVITY WARNING: This news story was originally posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are viewing this news story on another website, it was illegally stolen and republished in violation of US & international copyright & trademark legislation. The original version of this news story can be viewed at https://www.dispatchtribunal.com/2018/04/22/brokerages-set-agile-therapeutics-agrx-target-price-at-7-67.html.
About Agile Therapeutics
Agile Therapeutics, Inc, a women's healthcare company, focuses on the development and commercialization of prescription contraceptive products for women. Its lead product candidate is Twirla, also known as AG200-15, a once-weekly prescription combination hormonal contraceptive patch, which completed Phase III clinical trials.
Receive News & Ratings for Agile Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agile Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.